The Use of BDDCS in Classifying the Permeability of Marketed Drugs
- 1.1k Downloads
We recommend that regulatory agencies add the extent of drug metabolism (i.e., ≥ 90% metabolized) as an alternate method in defining Class 1 marketed drugs suitable for a waiver of in vivo studies of bioequivalence. That is, ≥ 90% metabolized is an additional methodology that may be substituted for ≥ 90% absorbed. We propose that the following criteria be used to define ≥ 90% metabolized for marketed drugs: Following a single oral dose to humans, administered at the highest dose strength, mass balance of the Phase 1 oxidative and Phase 2 conjugative drug metabolites in the urine and feces, measured either as unlabeled, radioactive labeled or nonradioactive labeled substances, account for ≥ 90% of the drug dosed. This is the strictest definition for a waiver based on metabolism. For an orally administered drug to be ≥ 90% metabolized by Phase 1 oxidative and Phase 2 conjugative processes, it is obvious that the drug must be absorbed. This proposal, which strictly conforms to the present ≥ 90% criteria, is a suggested modification to facilitate a number of marketed drugs being appropriately assigned to Class 1.
Key WordsBCS BDDCS bioequivalence elimination pathways
Biopharmaceutics Classification System
Biopharmaceutics Drug Disposition Classification System
This work was supported in part by NIH Grant GM 075900.
- 2.Food and Drug Administration, Guidance for Industry: Waiver of in vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Food and Drug Administration, Rockville, MD, 2000. Retrieved from www.fda.gov/cder/guidance/index.htm
- 3.J. E. Polli, L. X. Yu, J. A. Cook, G. L. Amidon, R. T. Borchardt, B. A. Burnside, P. S. Burton, M. -L. Chen, D. P. Conner, J. Faustino, A. A. Hawi, A. S. Hussain, H. N. Joshi, G. Kwei, V. H. L. Lee, L. J. Lesko, R. A. Lipper, A. E. Loper, S. G. Nerurkar, J. W. Polli, D. R. Sanvordeker, R. Taneja, R. S. Uppoor, C. S. Vattikonda, I. Wilding, and G. Zhang. Summary Workshop Report: Biopharmaceutics Classification System–Implementation Challenges and Extension Opportunities. J. Pharm. Sci. 93:1375–1381 (2004).PubMedCrossRefGoogle Scholar
- 6.H. Lennernas, L. Knutson, T. Knutson, L. Lesko, T. Salomonson, and G. L. Amidon. Human effective permeability data for furosemide, hydrochlorothiazide, ketoprofen and naproxen to be used in the proposed biopharmaceutical classification for IR-products. Pharm. Res. 12:S396 (1995).Google Scholar
- 8.D. Nillson, U. Fagerholm, and H. Lennernäs. The influence of net water absorption on the permeability of antipyrine and levodopa in the human jejunum. Pharm. Res. 11:1541–1545 (1994).Google Scholar
- 12.N. Takamatsu, L. S. Welage, N. M. Idkaidek, D. Y. Liu, P. I. Lee, Y. Hayashi, J. K. Rhie, H. Lennernäs, J. L. Barnett, V. P. Shah, L. Lesko, and G. L. Amidon. Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion. Pharm. Res. 14:1127–1132 (1997).PubMedCrossRefGoogle Scholar
- 14.X. Cao, S. T. Gibbs, L. Fang, H. A. Miller, C. P. Landowski, H-C. Shin, H. Lennernäs, Y. Zhong, G. L. Amidon, L. X Yu, and D. Sun. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm. Res. 23:1675–1686 (2006).PubMedCrossRefGoogle Scholar
- 17.N. A. Kasim, M. Whitehouse, C. Ramachandran, M. Bermejo, H. Lennernäs, A. S. Houssain, H. E. Junginger, S. A. Stavchansky, K. K. Midha, V. P. Shah, and G. L. Amidon. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol. Pharm 1:85–96 (2004).PubMedCrossRefGoogle Scholar
- 19.S. Tolle-Sander, and J. E. Polli. Method considerations for Caco-2 permeability assessment in the Biopharmaceutics Classification System. Pharmacop. Forum 28:164–172 (2002).Google Scholar
- 22.S. Sahin, J.M. Custodio and L.Z. Benet. Transepithelial transport of verapamil across Caco-2 cell monolayers. AAPS Journal. 2007; 9(S2). Abstract T3480. Available from http://www.aapsj.org/.
- 28.World Health Organization, Multisource (Generic) Pharmaceutical Products: Guidelines on Registration Requirements to Establish Interchangeability. WHO Technical Report Series, No. 937,2006, Annex 7, 347–390 (2006).Google Scholar